WWW.DISSERTATION.XLIBX.INFO
FREE ELECTRONIC LIBRARY - Dissertations, online materials
 
<< HOME
CONTACTS



Pages:   || 2 |

«Package Leaflet: Information for the patient EPANUTIN® 30 mg/ 5ml Oral Suspension (phenytoin) Read all of this leaflet carefully before you start ...»

-- [ Page 1 ] --

Package Leaflet: Information for the patient

EPANUTIN® 30 mg/ 5ml Oral Suspension

(phenytoin)

Read all of this leaflet carefully before you start taking this medicine because it contains

important information for you.

• Keep this leaflet. You may need to read it again.

• If you have any further questions, ask your doctor or pharmacist.

• This medicine has been prescribed for you only. Do not pass it on to others. It may harm

them, even if their signs of illness are the same as yours.

• If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. See section 4.

What is in this leaflet:

1. What Epanutin is and what it is used for

2. What you need to know before you take Epanutin

3. How to take Epanutin

4. Possible side effects

5. How to store Epanutin

6. Contents of the pack and other information

1. What Epanutin is and what it is used for This medicine contains phenytoin, which is one of a group of medicines called anti-epileptic drugs; these medicines are used to treat epilepsy.

Epanutin can be used to control epilepsy, to control or prevent seizures during or after brain surgery or severe head injury. Epanutin can also be used to treat trigeminal neuralgia (facial nerve pain).

You should consult your doctor if you are unsure why you have been given Epanutin 30mg/5ml Oral Suspension if you do not feel better or if you feel worse.

2. What you need to know before you take Epanutin Do not take Epanutin

• if you are allergic (hypersensitive) to phenytoin, or any of the other ingredients of this medicine (listed in section 6)

• if you are allergic to other medicines for epilepsy

• if you are also taking delavirdine (used for HIV therapy).

Warnings and precautions Talk to your doctor or pharmacist before you take Epanutin if you suffer from or have suffered in

the past from any of the following conditions:

• Liver disease

• Porphyria (an inherited disease that affects haemoglobin biosynthesis)

• Alcohol dependence.

Page 1 of 7 A small number of people being treated with antiepileptics such as phenytoin have had thoughts of harming or killing themselves. If at any time you have these thoughts, immediately contact your doctor.

Potentially life-threatening skin rashes (Stevens Johnson syndrome, toxic epidermal necrolysis) have been reported with the use of Epanutin, appearing initially as reddish target-like spots or circular patches often with central blisters on the trunk. Additional signs to look for include ulcers in the mouth, throat, nose, genitals and conjunctivitis (red and swollen eyes). These potentially life-threatening skin rashes are often accompanied by flu-like symptoms. The rash may progress to widespread blistering or peeling of the skin. The highest risk for occurrenceof serious skin reactions is within the first weeks of treatment. If you have developed Stevens-Johnson syndrome or toxic epidermal necrolysis with the use of Epanutin, you must not be re-started on Epanutin at any time.

If you develop a rash or these skin symptoms, stop taking Epanutin, seek urgent advice from a doctor and tell him that you are taking this medicine. Consult your doctor before discontinuing Epanutin. If you suddenly stop taking this medicine you may have a seizure.

This risk of these serious skin side effects may be associated with a variant in genes in a subject with Chinese or Thai origin. If you are of such origin and have been tested previously carrying this genetic variant (HLA-B*1502), discuss this with your doctor before taking Epanutin.

Black patients may be at greater risk of liver problems, serious skin reactions and allergic reactions.

Other medicines and Epanutin Tell your doctor or pharmacist if you are taking, have recently taken or might take any other medicines, including medicines obtained without a prescription.

Some medicines can affect the way Epanutin works, or Epanutin itself can reduce the

effectiveness of other medicines taken at the same time. These include:

• Medicines used for heart and circulation problems (e.g. dicoumarol, digitoxin, digoxin, mexiletine, nisoldipine, amiodarone, furosemide, quinidine, reserpine, warfarin, and calcium channel blockers including diltiazem and nifedipine)

• Medicines used for epilepsy (e.g. carbamazepine, lamotrigine, phenobarbital, sodium valproate and valproic acid, topiramate, oxcarbazepine, succinimides including ethosuximide and vigabatrin)

• Medicines used to treat fungal infections (e.g. amphotericin B, fluconazole, itraconazole, ketoconazole, posaconazole, voriconazole and miconazole)

• Medicines used for tuberculosis and other infections (e.g. chloramphenicol, isoniazid, rifampicin, sulfonamides, sulfadiazine, sulfamethiazole, sulfamethoxazole-trimethoprim, sulfaphenazole, sulfisoxazole, doxycycline and ciprofloxacin)

• Medicines used for stomach ulcers (e.g. omeprazole, sucralfate, the medicines known as H2 antagonists including cimetidine, ranitidine, famotidine and some antacids)

• Medicines used for asthma and bronchitis (e.g. theophylline)

• Medicines used for pain and inflammation (e.g. phenylbutazone, salicylates including aspirin and steroids)





• Medicines used for sleeplessness, depression and psychiatric disorders (e.g.

chlordiazepoxide, clozapine, diazepam, disulfiram, fluoxetine, methylphenidate, Page 2 of 7 paroxetine, phenothiazines, quetiapine, trazodone, tricyclic antidepressants, fluvoxamine, sertraline and viloxazine) Medicines used for diabetes (e.g. tolbutamide) • Medicines used for cancer (e.g. antineoplastic agents e.g. teniposide, fluorouracil), • capecitabine, bleomycin, carboplatin, cisplatin, doxorubicin and methotrexate Some hormone replacement therapies (oestrogens), oral contraceptives (the birth control • pill) Medicines used for organ and tissue transplants, to prevent rejection (e.g. ciclosporin, • tacrolimus) Medicines used to lower high blood cholesterol and triglycerides (e.g. atorvastatin, • fluvastatin, simvastatin) Medicines used in the treatment of HIV infection (e.g. delavirdine, efavirenz, • fosamprenavir, indinavir, lopinavir, nelfinavir, ritonavir, saquinavir) Medicines used to expel parasitic worms from the body (e.g. albendazole, praziquantel) • Muscle relaxants used for surgery (neuromuscular blockers), some anaesthetic drugs (e.g.

• halothane, methadone) Some products available without a prescription (e.g. folic acid, vitamin D).

• Your doctor may need to test the amount of phenytoin in your blood to help decide if any of these drugs are affecting your treatment.

The herbal preparation St John’s wort (Hypericum perforatum) should not be taken at the same time as this medicine. If you already take St John’s wort, consult your doctor before stopping the St John’s wort preparation.

If you are being fed by a tube this can affect the concentrations of phenytoin, the active ingredient of Epanutin 30 mg/5 ml Oral Suspension, in your blood. Your doctor or pharmacist will tell you how to take this medicine with your feeds.

Epanutin 30 mg/5 ml Oral Suspension may also interfere with certain laboratory tests that you may be given.

Epanutin with food, drink and alcohol Epanutin can be taken before or after food and drink.

Drinking a lot of alcohol can also affect the concentration of phenytoin in your blood.

Talk to your doctor or pharmacist for advice.

Pregnancy and breast-feeding If you are pregnant, think you may be pregnant, or are planning to have a baby, ask your doctor or pharmacist for advice before taking this medicine.

You should not breast-feed if you are taking Epanutin.

Driving and using machines Epanutin may cause dizziness or drowsiness. If you experience these symptoms, do not drive or use any tools or machinery and contact your doctor.

Epanutin contains sucrose, ethanol and the colouring agents sunset yellow (E110) and carmoisine (E122).

–  –  –

Epanutin contains sucrose, a type of sugar. If you have been told that you have an intolerance to some sugars, contact your doctor before taking this medicinal product. This medicine may be harmful to the teeth.

This medicine contains the colouring agents sunset yellow (E110) and carmoisine (E122) that may cause allergic reactions.

3. How to take Epanutin Always take this medicine exactly as your doctor or pharmacist has told you. Check with your doctor or pharmacist if you are not sure.

Shake the bottle vigorously before you measure your dose. Always use a medicine spoon or measure.

It is best to take Epanutin at the same time each day.

Adults The amount of Epanutin needed varies from one person to another. Most adults need between 200mg and 500mg a day (between 7 and 17 five-ml spoonfuls of Suspension) either as a single or divided dose. Occasionally higher doses are needed.

Use in Children and adolescents Infants and children usually start on a dose that depends on their weight (5mg per day for every kg they weigh) and is given as a divided dose, twice a day. The dose is then adjusted up to a maximum of 300mg a day (10 five-ml spoonfuls of Suspension).

Older people The dose of Epanutin for older people who may be taking other medicines may also need careful consideration and adjustment by their doctor.

If you take more Epanutin than you should Epanutin is dangerous in overdose. If you accidentally take too much Epanutin contact your doctor at once or go to the nearest hospital casualty department. Always take the labelled medicine package with you, whether there is any Epanutin left or not.

If you forget to take Epanutin If you forget to take a dose, take it as soon as you remember unless it is time for your next dose.

Do not take a double dose to make up for a missed dose.

If you stop taking Epanutin Do not stop taking Epanutin unless your doctor tells you to. If you suddenly stop taking this medicine you may have a seizure. Your doctor will advise you how to stop taking the medicine.

If you have any further questions on the use of this medicine, ask your doctor or pharmacist.

4. Possible side effects

–  –  –

Tell your doctor immediately if you experience any of the following symptoms after taking this medicine. Although they are very rare, these symptoms can be serious.

• Sudden wheeziness, difficulty in breathing, swelling of eyelids, face or lips, rash or itching (especially affecting the whole body). There is a higher incidence of this in black patients.

• If you develop potentially life-threatening skin rashes that cause blistering, (this can also affect the mouth and tongue). These may be signs of a condition known as Stevens Johnson syndrome, or toxic epidermal necrolysis (TEN). These have been reported very rarely.

• If you notice bruising, fever, you are looking pale or you have a severe sore throat. These may be the first signs of an abnormality of the blood, including decreases in the number of red cells, white cells or platelets. Your doctor may take regular blood samples to test for these effects.

• Skin rash and fever with swollen glands, particularly in the first two months of treatment, as these may be signs of a hypersensitivity reaction. If these are severe and you also experience pain and inflammation of the joints this could be related to a condition called systemic lupus erythematosus.

• Skin rash, fever, swollen glands, increase in a type of white blood cell (eosinophilia) and inflammation of internal organs (liver, lungs, heart, kidneys and large intestine) as they may be signs of a hypersensitivity reaction (Drug Reaction or rash with Eosinophilia and Systemic Symptoms (DRESS)).

• If you experience confusion or have a severe mental illness, as this may be a sign that you have high amounts of phenytoin in your blood. Your doctor may test your blood to see how much phenytoin is in the blood and may change your dose.

Other side effects that may occur are:

• Effects on your nervous system: Unusual eye movements, unsteadiness, difficulty in controlling movements, shaking, abnormal or uncoordinated movements, slurred speech, confusion, pins and needles or numbness, drowsiness, dizziness, vertigo, sleeplessness, nervousness, twitching muscles, headaches and change in taste.

• Effects on your skin: skin rash including measles-like reactions which are mild.

• Effects on your stomach and intestines: feeling sick, being sick and constipation.

• Effects on your blood and lymph system: swelling of the lymph glands.

• Effects on your liver and kidney: inflammation of the kidneys and liver, liver damage or liver failure which can lead to death (seen as yellowing of the skin and whites of the eye).

• Effects on your reproductive system and breasts: changes in the shape of the penis, painful erection.

• Effects on your hands, face and body: changes in the hands with difficulty in straightening the fingers, changes in facial features, enlarged lips or gums, increased or abnormal body or facial hair.

• Effects on medical tests: increased levels of blood sugar, or decreased levels of blood calcium, phosphate, folic acid and vitamin D. If you also do not get enough vitamin D in your diet or from exposure to sunlight, you may suffer from bone pain or fractures.

• Effects on your respiratory system: problems breathing, inflammation of the lining of the lung.

• Effects on your immune system: problems with the body’s defence against infection, inflammation of the wall of the arteries and immunoglobin abnormalities.

–  –  –

Reporting of side effects If you get any side effects, talk to your doctor or pharmacist. This includes any possible side effects not listed in this leaflet. You can also report any side effects directly (see details below).

By reporting side effects you can help provide more information on the safety of this medicine.

United Kingdom Yellow Card Scheme website: www.mhra.gov.uk/yellowcard Malta ADR Reporting website: www.medicinesauthority.gov.mt/adrportal



Pages:   || 2 |


Similar works:

«ACT Government Gazette Gazetted Notices for the week beginning 1 September 2016 Published by Shared Services | 01 September 2016 | © Australian Capital Territory, Canberra, 2016 ACT Government Gazette | 01 September 2016 VACANCIES Calvary Health Care ACT (Public) Medical Senior Medical Registrar Senior Registrar $134,599, Canberra (PN:TBA) Gazetted: 25 August 2016 Closing Date: 2 September 2016 Full position details can be seen on Calvary Public Hospital Bruce's website,...»

«DIABETESGUIDE Tips and advice from your pharmacist. Rite Aid Pharmacists: Your Dedicated Diabetes Experts. American Diabetes Association Partnership Rite Aid is committed to providing the everyday products and services that help our valued customers lead healthier, happier lives. An important part of that quality service is found in customer education. That’s why Rite Aid has worked together with the American Diabetes Association (ADA) to produce this valuable diabetes guide. The ADA is the...»

«ASX RELEASE 30 March 2012 LONRHO MINING LIMITED (ASX: LOM) QUARTERLY REPORT FOR PERIOD ENDED 29 FEBRUARY 2012 HIGHLIGHTS · Former Rio Tinto Diamonds MD, Gordon Gilchrist, appointed Chairman as part of Board revamp. · $12.7 million capital raising completed to fund new program to drill test 61 priority kimberlite targets within the Lulo Concession. · New $3.5 million Dense Media Separation diamond recovery plant and $1 million fleet of earthmoving equipment purchased for kimberlite...»

«Biographical Sketch CURRICULUM VITAE Name: Guy H. Loneragan Title: Professor of Food Safety and Public Health, and Faculty Fellow Address: Texas Tech Univ., MS 42141, Lubbock, Texas 79409-2141 Telephone: (806)834-1291 Fax: () E-mail: Guy.Loneragan@ttu.edu A. Education/Training YEAR INSTITUTION AND LOCATION DEGREE FIELD OF STUDY (s) 1999Colorado State University, Ft. Collins, CO PhD Epidemiology 2001 1996Population and Colorado State University, Ft. Collins, CO MS 1998 production medicine...»

«AMERICA'S HEALTHCARE SYSTEM Discussion and Analysis of Problems and Solutions Yuri C. Feynberg, PhD TABLE OF CONTENTS CHAPTER 1 INTRODUCTION Statement of the Problem Purpose of the Study Importance of the Study Scope of the Study Rationale of the Study Definition of Terms Overview of the Study CHAPTER 2 REVIEW OF RELATED LITERATURE Privatization and Healthcare in America Socialization and the Healthcare System Factors Affecting United States Healthcare Market Impacts International Developments...»

«Dog Owners and Breeders Symposium July 28, 2001 University of Florida College of Veterinary Medicine *Dilated Cardiomyopathy in Dogs *Overview of Canine Dental Health and Disease *Nutrition for Working Dogs *Intervertebral Disc Disease *Gastric Dilatation Volvulus *Canine Geriatric Medicine *Research Priorities Identified by AKC Parent Clubs *Current Concepts in Veterinary Ophthalmology *Advanced Reproduction Symposium *Feeding Dogs for Life Stages *An Introduction to Acupuncture *Management of...»

«Responsibilities of coaches and referees (Medical advice for coaches and referees) Sean Donnelly Abstract This paper addresses two areas of responsibility in the sport of amateur boxing – namely the responsibilities of the coach and the responsibilities of the referees. The author will look at the two roles, mainly from the medical perspective. I The Coach The person who becomes a coach is usually someone with enthusiasm offering him or herself to a club. Often the individual will have a...»

«2013 MONOGRAPH Highlights from FAMRI Funded Research FAMRI’s mission is to sponsor scientific and medical research for the early detection and cure of diseases and medical conditions caused from exposure to tobacco smoke.TABLE OF CONTENTS FOREWORD....................................................... 5 SCREENING CENTERS............................................... 7 HIGHLIGHTS OF...»

«Something to think About motivAtionS, AttitudeS, PercePtionS And SkillS in Work heAlth And SAfety SePtember 2011 Something to Think About – Motivations, Attitudes, Perceptions and Skills in Work Health and Safety A Review of the Literature on Socio-Psychological Factors and Their Influence on Organisations’ and Individuals’ Responses to Regulation Dr Liz Bluff Regulatory Institutions Network Australian National University Report prepared for Safe Work Australia August 2011 Disclaimer The...»

«Main operational lessons learnt from the WHO Pandemic Influenza A(H1N1) Vaccine Deployment Initiative Report of a WHO Meeting held in Geneva, Switzerland, 13–15 December 2010 WHO Library Cataloguing-in-Publication Data Main operational lessons learnt from the WHO Pandemic Influenza A(H1N1) Vaccine Deployment Initiative.1.Influenza A virus, H1N1 subtype immunology. 2.Influenza vaccines supply and distribution. 3.Pandemics prevention and control. 4.Influenza, Human virology. 5.International...»

«Herpes Zoster: [Print] eMedicine Dermatology http://emedicine.medscape.com/article/1132465-print emedicine.medscape.com eMedicine Specialties Dermatology Viral Infections Herpes Zoster Joseph S Eastern, MD, Clinical Assistant Professor, Department of Internal Medicine, Section of Dermatology, University of Medicine and Dentistry of New Jersey Updated: Oct 25, 2010 Introduction Background Zoster is a common, predominantly dermal, and neurologic disorder caused by the varicella-zoster virus...»

«IN THE COMMONWEALTH COURT OF PENNSYLVANIA Lancaster Emergency Medical : Services Association, : Petitioner : : v. : No. 1749 C.D. 2014 : Submitted: April 10, 2015 Unemployment Compensation : Board of Review, : Respondent : BEFORE: HONORABLE RENÉE COHN JUBELIRER, Judge HONORABLE ROBERT SIMPSON, Judge HONORABLE ANNE E. COVEY, Judge OPINION NOT REPORTED MEMORANDUM OPINION BY JUDGE SIMPSON FILED: June 4, 2015 Lancaster Emergency Medical Services Association (Employer) petitions for review from an...»





 
<<  HOME   |    CONTACTS
2016 www.dissertation.xlibx.info - Dissertations, online materials

Materials of this site are available for review, all rights belong to their respective owners.
If you do not agree with the fact that your material is placed on this site, please, email us, we will within 1-2 business days delete him.